Abbreviated New Drug Application process
E642120
The Abbreviated New Drug Application process is the U.S. regulatory pathway that allows generic drug manufacturers to gain FDA approval by demonstrating bioequivalence to an already approved brand-name drug without repeating full clinical trials.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Abbreviated New Drug Application process canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T7110943 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Abbreviated New Drug Application process Context triple: [Drug Price Competition and Patent Term Restoration Act of 1984, establishes, Abbreviated New Drug Application process]
-
A.
FDA traditional approval
FDA traditional approval is the U.S. Food and Drug Administration’s standard, full marketing authorization pathway granted when a drug has demonstrated substantial evidence of safety and effectiveness through adequate and well-controlled studies.
-
B.
Food and Drug Administration Modernization Act of 1997
The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
-
C.
Food and Drug Administration Amendments Act of 2007
The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
-
D.
340B Drug Pricing Program
The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
-
E.
Orphan Drug Act of 1983
The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Abbreviated New Drug Application process Target entity description: The Abbreviated New Drug Application process is the U.S. regulatory pathway that allows generic drug manufacturers to gain FDA approval by demonstrating bioequivalence to an already approved brand-name drug without repeating full clinical trials.
-
A.
FDA traditional approval
FDA traditional approval is the U.S. Food and Drug Administration’s standard, full marketing authorization pathway granted when a drug has demonstrated substantial evidence of safety and effectiveness through adequate and well-controlled studies.
-
B.
Food and Drug Administration Modernization Act of 1997
The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
-
C.
Food and Drug Administration Amendments Act of 2007
The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
-
D.
340B Drug Pricing Program
The 340B Drug Pricing Program is a U.S. federal initiative that requires drug manufacturers to provide outpatient medications to eligible healthcare organizations at significantly reduced prices to support care for underserved patients.
-
E.
Orphan Drug Act of 1983
The Orphan Drug Act of 1983 is a U.S. law that incentivizes the development of treatments for rare diseases by offering benefits such as market exclusivity, tax credits, and research grants to drug manufacturers.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
drug approval process
ⓘ
regulatory approval pathway ⓘ |
| administeredBy | FDA Center for Drug Evaluation and Research NERFINISHED ⓘ |
| applicableTo | small-molecule drug products ⓘ |
| appliesTo | generic drugs ⓘ |
| associatedWith | Orange Book listings NERFINISHED ⓘ |
| basedOn | Abbreviated New Drug Application NERFINISHED ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| difference |
does not require independent demonstration of clinical efficacy
ⓘ
relies on prior findings of safety and effectiveness for reference listed drug ⓘ |
| differsFrom | New Drug Application process ⓘ |
| documentationForm | electronic common technical document ⓘ |
| doesNotRequire |
full clinical efficacy trials
ⓘ
independent safety trials equivalent to new drug applications ⓘ |
| goal |
to avoid unnecessary duplication of clinical trials
ⓘ
to increase availability of lower-cost generic medicines ⓘ |
| impact | reduces drug costs for patients and payers ⓘ |
| includesStep |
FDA filing review
ⓘ
bioequivalence assessment ⓘ facility inspection ⓘ final approval or tentative approval decision ⓘ labeling review ⓘ submission of ANDA to FDA ⓘ substantive scientific review ⓘ |
| involves | patent and exclusivity considerations ⓘ |
| jurisdiction | Center for Drug Evaluation and Research NERFINISHED ⓘ |
| keyRequirement | demonstration of bioequivalence to a reference listed drug ⓘ |
| mayResultIn |
approval
ⓘ
complete response letter ⓘ tentative approval ⓘ |
| notTypicallyUsedFor | biologic products ⓘ |
| purpose | to provide a pathway for approval of generic versions of previously approved drugs ⓘ |
| referenceProduct | reference listed drug ⓘ |
| referenceProductType | previously approved brand-name drug ⓘ |
| regulatoryAgency |
FDA
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| regulatoryBasis | Federal Food, Drug, and Cosmetic Act NERFINISHED ⓘ |
| regulatorySection | Section 505(j) of the Federal Food, Drug, and Cosmetic Act ⓘ |
| relatedTo | New Drug Application process ⓘ |
| requires |
bioequivalence studies
ⓘ
chemistry, manufacturing, and controls information ⓘ drug product quality data ⓘ good manufacturing practice compliance ⓘ in vitro dissolution data where applicable ⓘ labeling information ⓘ patent certification ⓘ stability data for the drug product ⓘ |
| shortName | ANDA process ⓘ |
| supports | generic drug competition ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Abbreviated New Drug Application process Description of subject: The Abbreviated New Drug Application process is the U.S. regulatory pathway that allows generic drug manufacturers to gain FDA approval by demonstrating bioequivalence to an already approved brand-name drug without repeating full clinical trials.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
Drug Price Competition and Patent Term Restoration Act of 1984
→
establishes
→
Abbreviated New Drug Application process
ⓘ